A critical review of oliceridine injection as an IV opioid analgesic for the management of severe acute pain

References

• Gan TJ, Habib AS, Miller TE, et al. Incidence, patient satisfaction, and perceptions of post-surgical pain: results from a US national survey. Curr Med Res Opin. 2014;30(1):149–160.
   PubMed Web of Science ®Google Scholar
• Gan TJ. Poorly controlled postoperative pain: prevalence, consequences, and prevention. J Pain Res. 2017;10:2287–2298.
   PubMed Web of Science ®Google Scholar
• Stephens J, Laskin B, Pashos C, et al. The burden of acute postoperative pain and the potential role of the COX-2-specific inhibitors. Rheumatology (Oxford). 2003;42(3):iii40–52.
   PubMedGoogle Scholar
• Small C, Laycock H. Acute postoperative pain management. Br J Surg. 2020;107(2):e70–e80.
   PubMedGoogle Scholar
• Gelman D, Gelmanas A, Urbanaitė D, et al. Role of multimodal analgesia in the evolving enhanced recovery after surgery pathways. Medicina (Kaunas). 2018;54(2). DOI:https://doi.org/10.3390/medicina54020020
   Google Scholar
• Shafi S, Collinsworth AW, Copeland LA, et al., Association of opioid-related adverse drug events with clinical and cost outcomes among surgical patients in a large integrated health care delivery system. JAMA Surg. 2018;153(8):757–763.
   PubMed Web of Science ®Google Scholar
• Echeverria-Villalobos M, Stoicea N, Todeschini AB, et al. Enhanced recovery after surgery (ERAS): a perspective review of postoperative pain management under eras pathways and its role on opioid crisis in the United States. Clin J Pain. 2020;36(3):219–226.
   PubMed Web of Science ®Google Scholar
• Koepke EJ, Manning EL, Miller TE, et al. The rising tide of opioid use and abuse: the role of the anesthesiologist. Perioper Med (London, England). 2018;7:16.
   PubMedGoogle Scholar
• Bohn LM, Lefkowitz RJ, Gainetdinov RR, et al. Enhanced morphine analgesia in mice lacking beta-arrestin 2. Science. 1999;286(5449):2495–2498.
   PubMed Web of Science ®Google Scholar
• Violin JD, Crombie AL, Soergel DG, et al. Biased ligands at G-protein-coupled receptors: promise and progress. Trends Pharmacol Sci. 2014;35(7):308–316.
   PubMed Web of Science ®Google Scholar
• Stahl EL, Bohn LM. Low intrinsic efficacy alone cannot explain the improved side effect profiles of new opioid agonists. Biochemistry. 2021. Epub ahead of print. PMID: 34468132; PMCID: PMC8885792. Epub ahead of print. PMID: 34468132; PMCID: PMC8885792. https://pubmed.ncbi.nlm.nih.gov/34468132/
   Google Scholar
• DeWire SM, Yamashita DS, Rominger DH, et al. A G protein-biased ligand at the mu-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J Pharmacol Exp Ther. 2013;344(3):708–717.
   PubMed Web of Science ®Google Scholar
• Viscusi ER, Webster L, Kuss M, et al. A randomized, phase 2 study investigating TRV130, a biased ligand of the mu-opioid receptor, for the intravenous treatment of acute pain. Pain. 2016;157(1):264–272.
   PubMed Web of Science ®Google Scholar
• Gan TJ, Wase L. Oliceridine, a G protein-selective ligand at the μ-opioid receptor, for the management of moderate to severe acute pain. Drugs Today (Barc). 2020;56(4):269–286.
   PubMed Web of Science ®Google Scholar
• Nafziger AN, Arscott KA, Cochrane K, et al. The influence of renal or hepatic impairment on the pharmacokinetics, safety, and tolerability of oliceridine. Clin Pharmacol Drug Dev. 2020;9(5):639–650.
   PubMed Web of Science ®Google Scholar
• Trevena. OLINVYK (oliceridine) injection, for intravenous use, [controlled substance schedule pending]: US prescribing information. [cited 2020 Dec 2]. Avaliable from: https://olinvyk.com/
   Google Scholar
• US Food & Drug Administration. FDA approves new opioid for intravenous use in hospitals, other controlled clinical settings [media release]. 2020 Aug 7. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-opioid-intravenous-use-hospitals-other-controlled-clinical-settings
   Google Scholar
• Singla NK, Skobieranda F, Soergel DG, et al., APOLLO-2: a randomized, placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the mu-opioid receptor, for management of moderate to severe acute pain following abdominoplasty. Pain Pract. 2019;19(7):715–731.
   PubMed Web of Science ®Google Scholar
• Viscusi ER, Skobieranda F, Soergel DG, et al. APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the micro-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy. J Pain Res. 2019;12:927–943.
   PubMed Web of Science ®Google Scholar
• Bergese SD, Brzezinski M, Hammer GB, et al. ATHENA: a phase 3, open-label study of the safety and effectiveness of oliceridine (TRV130), A G-protein selective agonist at the µ-opioid receptor, in patients with moderate to severe acute pain requiring parenteral opioid therapy. J Pain Res. 2019;12:3113–3126.
   PubMed Web of Science ®Google Scholar
• Pathan H, Williams J. Basic opioid pharmacology: an update. Br J Pain. 2012;6(1):11–16.
   PubMedGoogle Scholar
• FDA. FDA briefing document. anesthetic and analgesic drug products advisory committee (AADPAC). 2018 Oct 11 [cited 2020 Sept 18]. Available from: https://www.fda.gov/media/121233/download
   Google Scholar
• Singla N, Hunsinger M, Chang PD, et al. Assay sensitivity of pain intensity versus pain relief in acute pain clinical trials: ACTTION systematic review and meta-analysis. J Pain. 2015;16(8):683–691.
   PubMedGoogle Scholar
• Moore RA, Edwards JE, McQuay HJ. Acute pain: individual patient meta-analysis shows the impact of different ways of analysing and presenting results. Pain. 2005;116(3):322–331.
   PubMed Web of Science ®Google Scholar
• Vase L, Wartolowska K. Pain, placebo, and test of treatment efficacy: a narrative review. Br J Anaesth. 2019;123(2):e254–e262.
   PubMedGoogle Scholar
• Moore RA, Moore OA, Derry S, et al. Numbers needed to treat calculated from responder rates give a better indication of efficacy in osteoarthritis trials than mean pain scores. Arthritis Res Ther. 2008;10(2):R39.
   PubMedGoogle Scholar
• Gan TJ, Belani KG, Bergese S, et al. Fourth consensus guidelines for the management of postoperative nausea and vomiting. Anesth Analg. 2020;131(2):411–448.
   PubMed Web of Science ®Google Scholar
• Beard TL, Michalsky C, Candiotti KA, et al. Oliceridine is associated with reduced risk of vomiting and need for rescue antiemetics compared to morphine: exploratory analysis from two phase 3 randomized placebo and active controlled trials. Pain Ther. 2020;10:401–413.
   PubMedGoogle Scholar
• Gupta K, Prasad A, Nagappa M, et al. Risk factors for opioid-induced respiratory depression and failure to rescue: a review. Curr Opin Anaesthesiol. 2018;31(1):110–119.
   PubMed Web of Science ®Google Scholar
• Cashman JN, Dolin SJ. Respiratory and haemodynamic effects of acute postoperative pain management: evidence from published data. Br J Anaesth. 2004;93(2):212–223.
   PubMed Web of Science ®Google Scholar
• Khanna AK, Bergese SD, Jungquist CR, et al., Prediction of opioid-induced respiratory depression on inpatient wards using continuous capnography and oximetry: an international prospective, observational trial. Anesth Analg. 2020;131(4):1012–1024.
   PubMed Web of Science ®Google Scholar
• Soergel DG, Subach RA, Burnham N, et al. Biased agonism of the mu- opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: a randomized, double-blind, placebo- controlled, crossover study in healthy volunteers. Pain. 2014;155(9):1829–1835.
   PubMed Web of Science ®Google Scholar
• Dahan A, van Dam CJ, Niesters M, et al. Benefit and risk evaluation of biased mu-receptor agonist oliceridine versus morphine. Anesthesiology. 2020;133(3):559–568.
   PubMed Web of Science ®Google Scholar
• Singla N, Minkowitz HS, Soergel DG, et al. A randomized, Phase IIb study investigating oliceridine (TRV130), a novel micro-receptor G-protein pathway selective (mu-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty. J Pain Res. 2017;10:2413–2424.
   PubMed Web of Science ®Google Scholar
• Ayad S, Demitrack MA, Burt DA, et al. Evaluating the incidence of opioid-induced respiratory depression associated with oliceridine and morphine as measured by the frequency and average cumulative duration of dosing interruption in patients treated for acute postoperative pain. Clin Drug Investig. 2020;40(8):755–764.
   PubMed Web of Science ®Google Scholar
• Brzezinski M, Hammer GB, Candiotti KA, et al. Low incidence of opioid-induced respiratory depression observed with oliceridine regardless of age or body mass index: exploratory analysis from a Phase 3 open-label trial in postsurgical pain. Pain Ther. 2021;10:457–473.
   PubMed Web of Science ®Google Scholar
• Ljungqvist O, Scott M, Fearon KC. Enhanced recovery after surgery: a review. JAMA Surg. 2017;152(3):292–298.
   PubMed Web of Science ®Google Scholar
• Shanthanna H, Ladha KS, Kehlet H, et al. Perioperative opioid administration. Anesthesiology. 2021;134(4):645–659.
   PubMedGoogle Scholar
• Gupta S, Mohta A, Gottumukkala V. Opioid-free anesthesia-caution for a one-size-fits-all approach. Perioper Med (London, England). 2020;9(16). DOI:https://doi.org/10.1186/s13741-020-00147-3
   Google Scholar
• Frauenknecht J, Kirkham KR, Jacot-Guillarmod A, et al. Analgesic impact of intra-operative opioids vs. opioid-free anaesthesia: a systematic review and meta-analysis. Anaesthesia. 2019;74(5):651–662.
   PubMed Web of Science ®Google Scholar
• Kharasch ED, Clark JD. Opioid-free anesthesia: time to regain our balance. Anesthesiology. 2021;134(4):509–514.
   PubMedGoogle Scholar
• Cicero TJ, Ellis MS, Kasper ZA. Polysubstance use: a broader understanding of substance use during the opioid crisis. Am J Public Health. 2020;110(2):244–250.
   PubMed Web of Science ®Google Scholar
• Glare P, Aubrey KR, Myles PS. Transition from acute to chronic pain after surgery. Lancet. 2019;393(10180):1537–1546.
   PubMed Web of Science ®Google Scholar
• Sebastian MP, Shanmuganathan S. Opioids in the postoperative period: a call for consensus. Br J Anaesth. 2019;122(6):e210–e211.
   PubMedGoogle Scholar